Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Denali Therapeutics Inc.NASDAQ: DNLI
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $97.02M fell 5.5% year over year, behind the -3.9% change in trailing-twelve-month research & development. Sequentially, it fell 6.6% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -5.5% toward the trailing-twelve-month pace of -3.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 418.78M USD
- Year-over-year change
- +5.6%
- 4-year CAGR
- +12.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 418.78M | +5.6% |
| FY2024 | 2024-12-31 | 396.44M | -6.5% |
| FY2023 | 2023-12-31 | 423.88M | +18.2% |
| FY2022 | 2022-12-31 | 358.73M | +35.2% |
| FY2021 | 2021-12-31 | 265.35M | — |
Research & Development vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's LTM Jun 2026 research & development of $400.72M is the 4th highest of the 11 companies compared; the peer median is $138.6M.
- Its year-over-year change of -3.9% is the 7th highest of 11, against a peer median of +7.2%.
- Research & development amounts to 11118.8% of revenue for DNLI, versus a peer median of 317.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.23B | +30.7% | +29.9% | 33.3% | |
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Jun 2026 | $467.76M | -32.9% | +13.3% | — | |
| LTM Jun 2026 | $400.72M | -3.9% | +5.3% | 11118.8% | |
| LTM Sep 2026 | $289.11M | +17.6% | +19.9% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Mar 2026 | $114.68M | -37.7% | -16.4% | 622.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Sep 2026 | $100.83M | +9.7% | -1.1% | — | |
| LTM Jun 2026 | $35.66M | +69.0% | -87.2% | — | |
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| Peer median (excluding DNLI) | $138.6M | +7.2% | +10.2% | 317.9% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.66M | 108.46M | 330.53M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.18M |
| Gross Profit | 48.66M | 108.46M | 330.53M | 0 | (11.18M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
| Selling, General & Admin | 79.06M | 90.48M | 103.35M | 105.44M | 97.1M |
| Operating Expenses | 344.41M | 449.21M | 527.23M | 487.34M | 544.16M |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| EBITDA | (282.56M) | (315.59M) | (128.47M) | (492.89M) | (497.63M) |
| EBITDA Margin | -580.7% | -291.0% | -38.9% | — | — |
| Operating Income | (295.75M) | (340.74M) | (196.7M) | (487.34M) | (555.34M) |
| Operating Margin | -607.8% | -314.2% | -59.5% | — | — |
| Interest Income | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Income Before Tax | (291.16M) | (325.97M) | (145.19M) | (422.71M) | (512.44M) |
| Pre-Tax Margin | -598.3% | -300.5% | -43.9% | — | — |
| Income Tax Expense | (575K) | 21K | 30K | 68K | 102K |
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Net Margin | -597.2% | -300.6% | -43.9% | — | — |
| EPS (Basic) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| EPS (Diluted) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| Weighted Avg Shares | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
| Weighted Avg Shares (Diluted) | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.